Digital Pathology & Imaging - software & AI news

Daily news on software, AI, and companies shaping digital pathology & imaging.

Showing 103 results
A tissue sample on a microscope slide in a lab setting

May 21, 2026

Roche to Acquire PathAI to Drive Diagnostics

Roche has announced its intent to acquire PathAI, a leader in digital pathology and AI diagnostics, in a move aimed at enhancing its capabilities in precision medicine.The acquisition, which follows a successful partnership initiated in 2021, will allow Roche to integrate PathAI's advanced digital pathology tools into its existing oncology diagnostic platforms. This integration is expected to streamline diagnostic workflows by transforming traditional manual processes into automated, AI-driven o
A prostate biopsy needle and sample in a clinical setting.

May 21, 2026

Prostate Cancer Diagnostics Market to Reach US$ 14.83 Billion by 2034 Amid Rising Cancer Awareness

The prostate cancer diagnostics market is on a robust growth trajectory, anticipated to expand from US$ 8.12 billion in 2025 to US$ 14.83 billion by 2034, reflecting a compound annual growth rate (CAGR) of 6.92% from 2026 to 2034. This growth is largely driven by heightened awareness of prostate cancer, government-supported screening initiatives, and advancements in diagnostic technologies.The increasing incidence of prostate cancer, particularly among men over 50, is a significant factor fuelin
A stethoscope and brain silhouette representing AI in healthcare

May 21, 2026

Guangzhou Kingmed Diagnostics Group Delivers Keynote Speech on "Digital and Intelligent Diagnostics Empowering a Global Community of Health for All" at the Global South Media and Think Tank Forum

Guangzhou Kingmed Diagnostics Group recently highlighted the role of digital intelligence in promoting healthcare equality during a keynote address at the Global South Media and Think Tank Forum in Cairo.Liang Xiaodan, Vice President of Kingmed, discussed the company's innovative approach to addressing disparities in medical resource distribution and diagnostic capabilities through an AI-driven "Medical Diagnostics + AI" model. This initiative aims to provide accessible, high-quality healthcare,
A blood sample in a test tube rack in a dimly lit lab setting.

May 20, 2026

Noul wins Korean funding to push AI blood analyzer toward US FDA, Europe

Noul has recently secured funding from the Korean government to propel its AI-driven blood analysis platform, miLab BCM, towards achieving regulatory approvals in the U.S. and Europe.The funding, amounting to 2.2 billion won (approximately $1.6 million), is part of a multi-ministerial initiative to support advanced medical device R&D. This investment aims to facilitate multinational pivotal studies that will generate essential clinical performance data for regulatory clearance and commercializat
A minimalist illustration of a heart and echocardiogram wave pattern.

May 19, 2026

Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts

Ventripoint Diagnostics is making strides in the AI cardiac imaging sector, capitalizing on a rapidly evolving procurement landscape.The landscape for medical artificial intelligence in cardiology is shifting dramatically, with hospitals increasingly seeking not just clinical accuracy but also economic justification before deploying new technologies. This trend has significant implications for companies like Ventripoint Diagnostics Ltd., which is leveraging its proprietary Knowledge Based Recons
Tissue sample on a lab bench with digital pathology equipment in the background.

May 18, 2026

Revolutionizing Cancer Care: AstraZeneca and Roche's Pioneering AI Partnership

AstraZeneca and Roche Diagnostics are embarking on a transformative three-year partnership aimed at enhancing cancer care in Asia through advanced AI-driven digital pathology.This collaboration marks a significant milestone as it introduces AI-powered digital pathology across nine Asian markets, focusing on education and training to foster the adoption of these technologies. Given that Asia accounts for nearly half of global breast cancer cases and over 60% of new lung cancer diagnoses, the need
A minimalist representation of a biomarker test strip with a sample drop.

May 18, 2026

AstraZeneca Collaborates with Roche Diagnostics Asia Pacific to Help Accelerate Sustainable Ecosystem for Advanced Pathology in Breast and Lung Cancer

AstraZeneca and Roche Diagnostics Asia Pacific have initiated a three-year partnership aimed at enhancing digital pathology capabilities and cancer care in nine Asian markets. This collaboration seeks to promote the use of AI-driven digital and computational pathology, particularly focusing on improving biomarker testing for breast and lung cancers.With nearly half of breast cancer cases and over 60% of new lung cancer diagnoses occurring in Asia, precise biomarker testing is increasingly vital
A mammogram displayed on a lightbox with a breast tissue sample in a clinical setting.

May 16, 2026

iCAD Inc stock (US45071L1098): AI breast cancer imaging specialist in the spotlight after recent bus

iCAD Inc, a prominent player in AI-driven breast cancer imaging and therapy solutions, is currently in the spotlight following a series of recent product and business updates that could shape its future in the medtech landscape.The company has made strides with its ProFound AI mammography platform and advancements in its therapy segment, emphasizing a strategic focus on scalable, software-driven cancer care. Market observers are keenly analyzing how these developments might affect iCAD's competi
Flat illustration of a CT scanner with radiation waves

May 16, 2026

Siemens Healthineers Pushes AI Oncology on the World Stage, but a Plodding Diagnostics Unit Drags th

Siemens Healthineers is making strides in AI-driven oncology with the launch of a photon-counting CT scanner, yet its diagnostics division is dragging down overall performance, affecting stock value.At the recent European Society for Radiotherapy and Oncology congress, Siemens Healthineers introduced the NAEOTOM Alpha Prime RT Pro Edition, an advanced CT scanner aimed at enhancing radiation therapy precision while reducing patient radiation exposure. This innovation highlights the company's stra
A liquid biopsy sample in a test tube on a lab bench

May 15, 2026

AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment

The landscape of cancer detection is evolving rapidly, driven by advancements in artificial intelligence and liquid biopsy technologies, according to BCC Research's latest report.The global molecular diagnostics market, valued at $20.3 billion in 2024, is projected to grow significantly, reaching $42.6 billion by 2030. This growth, estimated at a compound annual growth rate (CAGR) of 13.1%, is fueled by technological innovations and increased investments in healthcare infrastructure. North Ameri
Minimalist illustration of a cancer cell and AI algorithm

May 15, 2026

Archimedis Digital Commits $2 Mn to Expand AI-Led Life Sciences Innovation

Archimedis Digital has announced a significant investment of $2 million aimed at enhancing its AI-driven initiatives within the life sciences sector, particularly in cancer diagnosis and scientific data management.This funding will facilitate the creation of AI-first solutions, specifically targeting applications in histopathology and oncology diagnostics. The investment comes as the demand for intelligent systems that boost speed, accuracy, and predictive capabilities in healthcare grows. Archi
A minimalist heart silhouette with circuit patterns, representing AI in cardiac diagnostics.

May 14, 2026

A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

VentriPoint Diagnostics Ltd., a Toronto-based AI cardiac diagnostics firm, has achieved significant milestones, underscoring its potential in the medtech landscape. The company’s VMS+™ 4.0 system recently garnered a prestigious Edison Award and is advancing towards regulatory approval in China, marking a critical step in its growth trajectory.The AI-driven cardiac diagnostics market is rapidly evolving, projected to reach approximately $2.78 billion by 2026 and surpass $14 billion by 2034. This